Literature DB >> 10103299

Atypical chronic lung disease patterns in neonates.

L Charafeddine1, C T D'Angio, D L Phelps.   

Abstract

OBJECTIVE: To determine, in the postsurfactant era, the incidence and clinical characteristics of infants with atypical versus traditionally defined bronchopulmonary dysplasia (BPD) among premature infants with birth weights <1251 g.
DESIGN: Retrospective cohort study.
SETTING: A single regional neonatal intensive care unit (level III/IV). PATIENTS: Two hundred thirty-two premature infants <1251 g at birth consecutively admitted during a 2-year period. MAIN OUTCOME MEASURE: Incidence of classic BPD and atypical chronic lung disease (CLD) (occurring without preceding respiratory distress or after recovery from respiratory distress).
RESULTS: Among 177 infants <1251 g who survived to 28 days, 27 (15%) had atypical CLD and 61 (34.5%) had classic BPD. Atypical CLD infants were significantly heavier and more mature than classic BPD infants (mean birth weights, 922 +/- 152 g vs 854 +/- 173 g; and mean gestational age, 26.8 +/- 1.3 weeks vs 26.1 +/- 1.6 weeks). Median duration of ventilator support (31 days; range, 2 to 127 vs 42 days; range, 4-145 days) and oxygen therapy (30 days; range, 11 to 163 vs 48 days; range, 19-180 days) were shorter in atypical CLD infants than in classic BPD infants.
CONCLUSION: Atypical CLD comprised 31% of total cases of CLD. Atypical CLD appears to be less severe than classic BPD. These data suggest that initial, acute lung injuries are not the sole antecedents of neonatal CLD.

Entities:  

Mesh:

Year:  1999        PMID: 10103299     DOI: 10.1542/peds.103.4.759

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  29 in total

Review 1.  Long term sequelae of bronchopulmonary dysplasia (chronic lung disease of infancy).

Authors:  E Eber; M S Zach
Journal:  Thorax       Date:  2001-04       Impact factor: 9.139

2.  Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia.

Authors:  Jen-Ruey Tang; S Ananth Karumanchi; Gregory Seedorf; Neil Markham; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-10-14       Impact factor: 5.464

Review 3.  Pathogenesis and treatment of bronchopulmonary dysplasia.

Authors:  Jason Gien; John P Kinsella
Journal:  Curr Opin Pediatr       Date:  2011-06       Impact factor: 2.856

Review 4.  Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension.

Authors:  Bradley A Maron; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2017-02-01       Impact factor: 21.405

5.  Developmental determinants and changing patterns of respiratory outcomes after preterm birth.

Authors:  Steven H Abman; Simon J Conway
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-03

Review 6.  Bronchopulmonary dysplasia.

Authors:  Bernard Thébaud; Kara N Goss; Matthew Laughon; Jeffrey A Whitsett; Steven H Abman; Robin H Steinhorn; Judy L Aschner; Peter G Davis; Sharon A McGrath-Morrow; Roger F Soll; Alan H Jobe
Journal:  Nat Rev Dis Primers       Date:  2019-11-14       Impact factor: 52.329

Review 7.  Ureaplasma and BPD.

Authors:  Suhas G Kallapur; Boris W Kramer; Alan H Jobe
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

8.  Bronchopulmonary dysplasia in preterm infants: pathophysiology and management strategies.

Authors:  Carl T D'Angio; William M Maniscalco
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 9.  Pulmonary Hypertension and Vascular Abnormalities in Bronchopulmonary Dysplasia.

Authors:  Peter M Mourani; Steven H Abman
Journal:  Clin Perinatol       Date:  2015-09-26       Impact factor: 3.430

10.  Prenatal inflammation and lung development.

Authors:  Boris W Kramer; Suhas Kallapur; John Newnham; Alan H Jobe
Journal:  Semin Fetal Neonatal Med       Date:  2008-10-08       Impact factor: 3.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.